Tobacco Master Settlement Agreement

Settlement Administrator Angeion Group Announces Proposed Settlement in In Re Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Litigation Class Action

Retrieved on:

Monday, December 11, 2023

PHILADELPHIA, Dec. 11, 2023 /PRNewswire/ -- A proposed Settlement of Economic Loss Claims has been reached in a U.S. class action lawsuit against Defendants Philips RS North America LLC ("Philips RS"), Koninklijke Philips N.V., Philips North America LLC, Philips Holding USA, Inc., and Philips RS North America Holding Corporation (collectively, the "Philips Defendants"), related to CPAP, BiPAP and ventilator devices sold in the United States between 2008 and 2021 that Philips RS recalled beginning in June 2021. Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective. The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.

Key Points:

If You Paid For A Philips CPAP, BIPAP, Or Ventilator That Was Recalled By Philips RS North America LLC Beginning in June 2021, A Class Action Settlement May Affect Your Legal Rights.
Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective.
The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.
You may be eligible to receive a payment if you paid for a Philips Respironics CPAP, BiPAP, or Ventilator that was recalled.

Settlement Administrator Angeion Group Announces Proposed Settlement in In Re Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Litigation Class Action

Retrieved on:

Monday, December 11, 2023

PHILADELPHIA, Dec. 11, 2023 /PRNewswire/ -- A proposed Settlement of Economic Loss Claims has been reached in a U.S. class action lawsuit against Defendants Philips RS North America LLC ("Philips RS"), Koninklijke Philips N.V., Philips North America LLC, Philips Holding USA, Inc., and Philips RS North America Holding Corporation (collectively, the "Philips Defendants"), related to CPAP, BiPAP and ventilator devices sold in the United States between 2008 and 2021 that Philips RS recalled beginning in June 2021. Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective. The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.

Key Points:

If You Paid For A Philips CPAP, BIPAP, Or Ventilator That Was Recalled By Philips RS North America LLC Beginning in June 2021, A Class Action Settlement May Affect Your Legal Rights.
Plaintiffs in this lawsuit allege that the particular type of noise-reducing foam used in the recalled devices was defective.
The Settlement is intended to resolve Economic Loss Claims only and does not affect or release any claims for personal injuries or medical monitoring relief.
You may be eligible to receive a payment if you paid for a Philips Respironics CPAP, BiPAP, or Ventilator that was recalled.

If You Received Inadequate Medical Care While Incarcerated at the Bradley County Jail Between September 18, 2017 Through November 29, 2023, Then You Could Be Entitled to Money From a Class Action Settlement

Retrieved on:

Monday, December 11, 2023

Arrest, Plaintiff, Class representative, Lawsuit, Defendant, Georgia Avenue, Vexatious litigation, District court, Settlement, Tobacco Master Settlement Agreement, Hearing, Court, National Incentive Award (KVS), Damages, BCSO, Insurance, Pharmaceutical industry, Prison

A lawsuit pending in the U.S. District Court for the Eastern District of Tennessee ("Litigation") may affect your rights.

Key Points:

A lawsuit pending in the U.S. District Court for the Eastern District of Tennessee ("Litigation") may affect your rights.
The Litigation claims that Bradley County, Tennessee, and the Bradley County Sheriff's Office ("BCSO") ("Defendants") maintained a system of constitutionally inadequate medical care at the Bradley County Jail (the "Jail") between September 18, 2017 through November 29, 2023 ("Class Period").
With Court approval, Damages Class Members who submit valid and timely Claim Forms may receive a cash award from the Settlement Fund.
In addition, a Damages Class Member may forego a full evaluation of his claim(s) and accept a smaller, guaranteed cash award.

Illinois Whistleblower Lawsuit Against Cricket Wireless, LLC Settles for $11 Million

Retrieved on:

Monday, December 4, 2023

Diamond, Sale, Circuit court, LLP, Accusative case, The Act, ST-1, Act, Tax, Relator (law), False Claims Act, Vexatious litigation, Cricket, P.C, Tobacco Master Settlement Agreement, Cricket Wireless, Government

Relators filed the False Claims Act lawsuit on behalf of the State of Illinois alleging Cricket Wireless caused its Illinois authorized retailers to omit payment of retailers' occupation tax with their ST-1 tax returns on $52 million of phone purchase discounts given to customers and reimbursed by Cricket.

Key Points:

Relators filed the False Claims Act lawsuit on behalf of the State of Illinois alleging Cricket Wireless caused its Illinois authorized retailers to omit payment of retailers' occupation tax with their ST-1 tax returns on $52 million of phone purchase discounts given to customers and reimbursed by Cricket.
The settlement pays 2.3 times the sales taxes owed on the $52 million of discounts Cricket reimbursed authorized retailers on 999,000 phones sold from July 2014 through June 30, 2019.
Relators and their counsel prosecuted the action against Cricket on behalf of the State of Illinois until two days before trial when Relators' counsel negotiated the settlement.
Under the Settlement Agreement, which became effective on November 29, 2023, Cricket Wireless agreed to pay the State of Illinois $11 million.

If You Were Fingerprinted by BioMetric Impressions Corp. on or after January 8, 2015, You May Be Eligible for a Cash Payment from a Class Action Settlement.

Retrieved on:

Thursday, November 23, 2023

Circuit court, Notice, Class representative, Class, BIPA, Vexatious litigation, CMS, Person, Settlement, BIC, Counsel, Tobacco Master Settlement Agreement, Court, Hearing

Although BIC denies the allegations and any wrongdoing, the parties have decided to settle their dispute (the "Settlement").

Key Points:

Although BIC denies the allegations and any wrongdoing, the parties have decided to settle their dispute (the "Settlement").
Each Class member who submits a timely, valid Claim Form may receive a payment out of the Settlement.
To receive a cash payment from the fund, you must complete and submit a Claim Form by February 22, 2024.
If you want, you can hire your own attorney at your own expense to appear or speak for you at the hearing.

CIRO Hearing Panel accepts settlement agreement with Miranda Sirri Che

Retrieved on:

Thursday, November 9, 2023

Investment, Corporation, Respondent, Ix, Vexatious litigation, CIRO, Settlement, Fine, Tobacco Master Settlement Agreement, Xi, Mutual Fund Dealers Association, Hearing, Dealer, Security (finance), Copper, Lease, Financial adviser, Saskatoon

TORONTO, Nov. 9, 2023 /CNW/ - A settlement hearing in the matter of Miranda Sirri Che (the "Respondent") was held electronically by videoconference on October 10, 2023 before a three-member Hearing Panel of the Saskatchewan District Hearing Committee of the Canadian Investment Regulatory Organization ("CIRO").

Key Points:

TORONTO, Nov. 9, 2023 /CNW/ - A settlement hearing in the matter of Miranda Sirri Che (the "Respondent") was held electronically by videoconference on October 10, 2023 before a three-member Hearing Panel of the Saskatchewan District Hearing Committee of the Canadian Investment Regulatory Organization ("CIRO").
A copy of the Settlement Agreement is available on the MFDA website at www.mfda.ca .
During the period described in the Settlement Agreement, the Respondent carried on business in the Saskatoon, Saskatchewan area.
CIRO is committed to the protection of investors, providing efficient and consistent regulation, and building Canadians' trust in financial regulation and the people managing their investments.

Notice Administrator Angeion Group Announces Proposed Settlement in Aqueous Film

Retrieved on:

Wednesday, October 25, 2023

PHILADELPHIA, Oct. 25, 2023 /PRNewswire/ -- Angeion Group today issues a reminder that a settlement has been reached with Defendant the 3M Company (3M) in a product liability class action lawsuit. Eligible claimants are all Active Public Water Systems in the U.S. that draw or otherwise collect from any Water Source that, on or before June 22, 2023, was tested or otherwise analyzed for PFAS and found to contain any PFAS at any level; and All Active Public Water Systems in the U.S. that, as of June 22, 2023, do not draw or otherwise collect from any Water Source that was tested or otherwise analyzed for PFAS and found to contain any PFAS at any level and (i) are required to test for certain PFAS under U.S. EPA's UCMR-5, or (ii) serve more than 3,300 people, according to U.S. EPA's SDWIS data system.

Key Points:

All other capitalized terms have the same meaning as in the Settlement Agreement, available at www.PFASWaterSettlement.com .
It is the intention of the Settlement Agreement that the definition of "Public Water System" be as broad, expansive, and inclusive as possible.
In no event shall 3M be required under the Settlement Agreement to pay any amounts above the Settlement Funds.
The Final Fairness Hearing may be postponed, adjourned, or continued by Order of the Court without further notice to the Class.

MediPharm Labs Update on $9M Settlement Agreement - All Tilray Shares Sold and Converted to Cash

Retrieved on:

Wednesday, October 25, 2023

FDA, Tobacco Master Settlement Agreement, US, Medicine, FSE, Settlement, TSX, Vexatious litigation, Pharmaceutical industry, Cryptocurrency, Tilray

On October 2, 2023 MediPharm and Tilray came to a mutually agreeable resolution and established a long-term supply relationship.

Key Points:

On October 2, 2023 MediPharm and Tilray came to a mutually agreeable resolution and established a long-term supply relationship.
Following the Settlement Agreement, MediPharm has now received $7.27 Million in cash consisting of:
1,573,152 total Tilray common shares that have been sold for gross proceeds of $4.27 Million.
Non-cash elements also included in the Settlement Agreement are ongoing product considerations:
§ $500,000 four-year supply agreement to provide Tilray with MediPharm products and services.
MediPharm has already started working closely with Tilray management to add MediPharm Labs products to Tilray's Medical platform, and to qualify the most appropriate products to be sourced from Tilray.

Notice Administrator Angeion Group Announces Proposed Settlement in Aqueous Film

Retrieved on:

Wednesday, October 18, 2023

PHILADELPHIA, Oct. 18, 2023 /PRNewswire/ -- Angeion Group today issues a reminder that a settlement has been reached with Defendants in a product liability class action lawsuit involving all Public Water Systems in the US that draw or otherwise collect from any water source that, on or before June 30, 2023, was tested or otherwise analyzed for PFAS and found to contain any PFAS at any level; and All Public Water Systems in the US that, as of June 30, 2023, are (i) subject to the monitoring rules set forth in the U.S. EPA's Fifth Unregulated Contaminant Monitoring Rule ("UCMR 5") (i.e., "large" systems serving more than 10,000 people and "small" systems serving between 3,300 and 10,000 people), or (ii) required under applicable state or federal law to test or otherwise analyze any of their water sources or the water they provide for PFAS before the deadline of sample collection under UCMR 5.

Key Points:

The Settling Defendants have agreed to pay $1,185,000,000, subject to final approval of the Settlement by the Court and certain other conditions specified in the Settlement Agreement.
In no event shall the Settling Defendants be required to pay any amounts under the Settlement Agreement above the Settlement Amount.
Any fees, costs, or expenses payable under the Settlement Agreement shall be paid out of, and shall not be in addition to, the Settlement Amount.
The Final Fairness Hearing may be postponed, adjourned, or continued by Order of the Court without further notice to the Class.

MediPharm Labs Settles an Outstanding Claim for $9M

Retrieved on:

Monday, October 2, 2023

Ontario Superior Court of Justice, New York Court of Appeals, Tilray, Justice, Ontario Court of Justice, Vexatious litigation, Tobacco Master Settlement Agreement, FSE, Sale, US, Medication, Acquisition, Hearing, TSX, Ageing, FDA, Pharma

TORONTO, Oct. 2, 2023 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a company specialized in precision-based cannabinoids, is pleased to announce it has entered into a settlement agreement on September 29, 2023 (the "Settlement Agreement") to resolve a claim in connection with a commercial agreement dispute, for a total consideration value of $9,000,000.

Key Points:

TORONTO, Oct. 2, 2023 /PRNewswire/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a company specialized in precision-based cannabinoids, is pleased to announce it has entered into a settlement agreement on September 29, 2023 (the "Settlement Agreement") to resolve a claim in connection with a commercial agreement dispute, for a total consideration value of $9,000,000.
On January 24, 2020, MediPharm Labs filed a statement of claim (the "Claim") in the Ontario Superior Court of Justice against one of its long-term customers, HEXO Corp., regarding a long-term supply agreement for cannabis concentrates.
MediPharm was awarded a favourable summary judgment in the Ontario Court of Justice in July of 2022.
In connection with the Settlement Agreement, Hexo Corp. will abandon its appeal as against MediPharm.